Qube Research & Technologies LTD Viking Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.4 - $94.5 $25,125 - $136,458	-1,444 Reduced 4.96%	27,688 $2.27 Million
Q4 2023 Feb 13, 2024	BUY	$9.24 - $19.64 $269,179 - $572,152	29,132 New	29,132 $542,000
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $50,650 - $77,267	19,863 Added 75.46%	46,186 $126,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $4,979 - $7,434	-2,360 Reduced 8.23%	26,323 $76,000
Q1 2022 May 09, 2022	BUY	$3.0 - $4.88 $52,836 - $85,946	17,612 Added 159.08%	28,683 $86,000
Q4 2021 Feb 01, 2022	BUY	$4.6 - $6.72 $50,926 - $74,397	11,071 New	11,071 $51,000
Q1 2021 May 14, 2021	SELL	$5.74 - $9.67 $64,041 - $107,888	-11,157 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $55,199 - $69,884	-10,415 Reduced 48.28%	11,157 $63,000
Q3 2020 Nov 12, 2020	SELL	$5.73 - $8.11 $102,137 - $144,560	-17,825 Reduced 45.24%	21,572 $126,000
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $171,376 - $318,327	39,397 New	39,397 $284,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.